Medical Information Notice: This article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified clinician for your personal situation.

Ovarian cancer develops in the ovaries, fallopian tubes, or peritoneum (the lining of the abdomen). It's often called a "silent killer" because symptoms are vague and typically appear at advanced stages. Here's a comprehensive overview:

  • Types of Ovarian Cancer

    • Epithelial Ovarian Cancer (EOC)
      • ~90% of cases. Arises from cells covering the ovary. Subtypes:
        • High-Grade Serous Carcinoma (HGSC): Most common (70-80%), aggressive, often linked to BRCA mutations.
        • Endometrioid, Clear Cell, Mucinous: Less common, varied aggressiveness.
        • Low-Grade Serous: Rare, slower-growing.
    • Germ Cell Tumors
      • ~5% of cases. Develop from egg-producing cells. It often affects younger women (teens/20s). Usually curable.
    • Stromal Tumors
      • ~5% of cases. Arise from hormone-producing cells (e.g., granulosa cell tumors). Can cause estrogen/testosterone excess.

  • Symptoms (Often Subtle & Late-Stage)

    • Early: Bloating, pelvic/abdominal pain, feeling full quickly, urinary urgency.
    • Advanced: Weight loss, fatigue, changes in bowel habits, ascites (fluid buildup), shortness of breath.
    • Key Insight: Symptoms persist >2 weeks and worsen. "B.E.A.T." mnemonic: Bloating, Eating less/fullness, Abdominal pain, Toilet changes.

  • Risk Factors

    • Age: Highest risk in women >50; peak incidence in 60s-70s.
    • Genetics:
      • BRCA1/BRCA2 mutations (↑ risk of HGSC).
      • Lynch syndrome (↑ risk of endometrioid/clear cell).
    • Reproductive History:
      • ↑ Risk: Nulliparity (no pregnancies), early menstruation, late menopause.
      • ↓ Risk: Oral contraceptive use, multiple pregnancies, breastfeeding.
    • Endometriosis: ↑ Risk for clear cell/endometrioid subtypes.
    • Family History: Ovarian, breast, or colorectal cancer.
    • Obesity: Linked to poorer outcomes.

  • Diagnosis

    • Pelvic Exam: May detect masses (limited sensitivity).
    • Imaging:
      • Transvaginal Ultrasound (TVUS): First-line for ovarian masses.
      • CT/MRI/PET-CT: Staging, metastasis detection.
    • Blood Tests:
      • CA-125: Elevated in 80% of advanced EOC (but not specific; can rise in endometriosis, menstruation).
      • HE4, ROMA Score: Complementary biomarkers.
    • Biopsy/Surgery:
      • Definitive diagnosis via tissue biopsy (often during surgery).
      • Staging laparotomy: Assesses spread (critical for treatment planning).

  • Treatment:

    • Surgery ("Debulking"):
      • Goal: Remove all visible tumor ("optimal cytoreduction").
      • Includes hysterectomy, omentectomy, and lymph node removal.
    • Chemotherapy:
      • First-line: Carboplatin + Paclitaxel (IV or IV + intraperitoneal).
      • Neoadjuvant chemo: Shrinks tumors before surgery (for advanced/unresectable cases).
    • Targeted Therapies:
      • PARP Inhibitors (Olaparib, Niraparib): Maintenance therapy for BRCA-mutated or HRD+ tumors.
      • Bevacizumab (Anti-VEGF): Inhibits blood vessel growth.
    • Hormone Therapy: For stromal/low-grade tumors (e.g., aromatase inhibitors).
    • Immunotherapy & Clinical Trials: Emerging role (e.g., checkpoint inhibitors).

  • Prognosis

    • 5-Year Survival:
      • Stage I: ~90%
      • Stage III: ~40%
      • Stage IV: ~20%
    • Key Factors: Stage, tumor subtype, residual disease post-surgery, BRCA status.

  • Prevention & Early Detection

    • High-Risk Women:
      • BRCA+: Risk-reducing salpingo-oophorectomy (removal of ovaries/tubes).
      • Regular TVUS + CA-125 (though screening not proven effective for average-risk women).
    • General: Birth control pills reduce risk by 30-50% with long-term use.

Frequently Asked Questions (FAQ)

Q1: Why is ovarian cancer called the "silent killer"?
Ovarian cancer is often called the "silent killer" because its early symptoms — bloating, pelvic pain, feeling full quickly, and urinary urgency — are vague and easy to dismiss as minor digestive or menstrual issues. As a result, approximately 75% of cases are not diagnosed until Stage III or IV, when the cancer has already spread widely.

Q2: What is the BEAT mnemonic for ovarian cancer symptoms?
BEAT stands for Bloating (persistent), Eating less or feeling full quickly, Abdominal or pelvic pain, and Toilet changes (increased urination urgency/frequency). These symptoms persisting for more than two weeks, especially if they are new or worsening, warrant evaluation by a doctor.

Q3: How do BRCA mutations relate to ovarian cancer?
Women with inherited BRCA1 or BRCA2 gene mutations have a significantly higher lifetime risk of developing ovarian cancer (particularly high-grade serous carcinoma). Women with BRCA mutations are typically offered enhanced surveillance or risk-reducing surgery (removal of ovaries and fallopian tubes) after completing childbearing, usually between ages 35–45.

Q4: Is CA-125 a reliable screening test for ovarian cancer?
CA-125 is a blood marker elevated in about 80% of advanced ovarian cancer cases, but it is not specific enough for general population screening — it can also be elevated in endometriosis, uterine fibroids, pelvic infections, and other conditions. It is most useful for monitoring treatment response and detecting recurrence in women already diagnosed with ovarian cancer.

Q5: What does "debulking surgery" mean in ovarian cancer?
Debulking (cytoreductive surgery) involves removing as much tumor as possible — ideally leaving no visible residual disease ("optimal cytoreduction"). It typically includes removal of the uterus, ovaries, fallopian tubes, omentum, and any affected lymph nodes. The amount of residual disease after surgery is one of the most important prognostic factors in ovarian cancer.

Q6: What are PARP inhibitors and how are they used in ovarian cancer?
PARP inhibitors (such as olaparib and niraparib) target cancer cells with deficient DNA repair machinery, particularly those with BRCA mutations or homologous recombination deficiency (HRD). They are used as maintenance therapy after chemotherapy, significantly prolonging the time before cancer recurs in eligible patients.

Q7: Can ovarian cancer be prevented?
There is no proven prevention method for the general population. However, long-term use of oral contraceptives reduces ovarian cancer risk by 30–50%. Breastfeeding and multiple pregnancies also provide some protection. For women with BRCA mutations, risk-reducing salpingo-oophorectomy (surgical removal of ovaries and fallopian tubes) is the most effective preventive intervention.

Medical Disclaimer

MediPulse publishes this content for patient education. It may not reflect the latest guideline changes in every jurisdiction. Do not delay seeking care because of something you read here.